Glenmark Pharmaceuticals moves up on launching Triple-drug FDC of Teneligliptin with Dapagliflozin and Metformin
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Glenmark Pharmaceuticals is currently trading at Rs. 809.05, up by 7.60 points or 0.95% from its previous closing of Rs. 801.45 on the BSE.
The scrip opened at Rs. 805.25 and has touched a high and low of Rs. 810.35 and Rs. 805.20 respectively. So far 3294 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 879.15 on 21-Sep-2023 and a 52 week low of Rs. 369.50 on 30-Jan-2023.
Last one week high and low of the scrip stood at Rs. 811.70 and Rs. 778.35 respectively. The current market cap of the company is Rs. 22614.37 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 34.67% and 18.69% respectively.
Glenmark Pharmaceuticals has launched in India the first triple-drug fixed-dose combination (FDC) of the widely used Teneligliptin with Dapagliflozin and Metformin. This FDC has been launched under the brand name Zita DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapagliflozin, (10mg), and Metformin SR (500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes.
Glenmark’s Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually, in India. With the launch of Zita DM, Zita the most comprehensive gliptin range now holds promise of helping Type 2 diabetic patients at every stage of their treatment.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
